ACAT1 and prostate adenocarcinoma: Interestingly, when performing the same analysis in the TCGA-PRAD dataset (n = 497), high expression of ACAT1, OXCT1 and BDH1 was associated with shorter progression-free survival (PFS) (Fig. 7A), while higher levels of HMGCL were associated with a longer PFS time.